AXSM Earnings Prediction
The chart below shows how AXSM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AXSM sees a -4.61% change in stock price 10 days leading up to the earnings, and a +3.24% change 10 days following the report. On the earnings day itself, the stock moves by +0.03%. This data can give you a slight idea of what to expect for the next quarter's release.
AXSM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
104.76M
81.27%
20.19%
Gross Margin
90.41%
5.23%
1.66%
Operating Margin
-44.13%
-59.06%
-49.31%
Net Margin
-61.67%
-42.70%
-32.25%
EPS
-1.34
-1.52%
-19.76%
No Data Available
AXSM Earnings Analysis
Axsome Therapeutics, Inc Corporation (AXSM.O) Earnings Conference Call
Positive
Record Quarterly Product Revenue: The third quarter was another strong quarter, it represented another novel milestone as we delivered quarterly product revenue in excess of $100 million for the first time.
Annual Revenue Run Rate: This quarterly performance translates to an annual revenue run rate of approximately $420 million, just three quarters into our second fully year as a commercial therapy.
Mission Progress Update: We are pleased to report on the progress we’ve made in advancing this important mission in the core, particularly, our long-term vision, and review potentially value-driving year and intermediate term milestones.
R&D Expense Increase: Our R&D expenses for Q3 were $45.4 million, compared to $28.8 million for the same period in 2023. The increase was primarily driven by our ongoing clinical programs for AXS-05 and solriamfetol, as well as increased chemistry, manufacturing, and controls costs associated with our pipeline products and higher personnel costs including non-cash stock-based compensation associated with organizational growth.
Strong Revenue Increase: We delivered yet another robust quarter and recorded total net product revenue of $104.8 million, compared to $57.8 million for the same period in 2023, representing an 81% year-over-year increase.
Negative
Quarterly Net Loss Comparison: Net loss for the third quarter was $64.6 million or $1.34 cents per share, compared to $62.2 million or $1.32 per share for the comparable period in 2023.
R&D Expense Increase: R&D expenses for Q3 were $45.4 million, compared to $28.8 million for the same period in 2023, indicating a significant increase in spending.
SG&A Expense Increase: SG&A expenses for the third quarter were $95.6 million, compared to $83.2 million for the same period in 2023, reflecting increased operational costs.
Net Product Revenue Increase: The company reported a net product revenue of $104.8 million, which, while an increase, still reflects challenges in achieving profitability.
Net Loss Increase Analysis: The increase in net loss includes $40.9 million in non-cash charges, indicating ongoing financial strain despite revenue growth.
AXSM FAQs
How does AXSM typically perform around its earnings report dates?
Is Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AXSM Earning Call Sentiment
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AXSM.O
4.03%Positive
The earnings call reveals strong financial performance with significant revenue growth and a solid cash position. Despite competitive pressures and supply chain challenges, the company is expanding its sales force and improving market access for Auvelity, which shows potential for further growth. The Q&A section indicates positive sentiment towards market expansion and product positioning. However, management was vague on certain specifics, which slightly tempers the optimism. Overall, with a market cap of approximately $3.8 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
